Share Price and Basic Stock Data
Last Updated: January 7, 2026, 11:53 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fabino Enterprises Ltd operates within the pharmaceuticals industry, with its stock currently priced at ₹13.2 and a market capitalization of ₹2.77 Cr. The company’s revenue has exhibited some volatility in recent years, with total sales standing at ₹3.36 Cr for the fiscal year ending March 2023, down from ₹4.19 Cr in March 2022. Notably, sales have been reported at ₹6.01 Cr for FY 2024 and projected to rise sharply to ₹18.00 Cr for FY 2025, indicating a significant expected rebound. However, the recent quarterly sales figures for September 2023 showed a decline to ₹0.94 Cr compared to ₹2.32 Cr in March 2023, highlighting potential short-term challenges. The trailing twelve-month (TTM) revenue is reported at ₹14.46 Cr, reflecting a recovery trend compared to previous fiscal years. This pattern suggests that while Fabino Enterprises has faced hurdles, particularly in the latter half of FY 2023, there are indications of a stronger performance in the upcoming fiscal periods.
Profitability and Efficiency Metrics
Fabino Enterprises reported a net profit of ₹0.00 Cr for March 2023, indicating a challenging profitability landscape, which is further exemplified by a negative net profit of ₹0.16 Cr for the same period. The operating profit margin (OPM) stood at -38.24% in September 2025, a stark contrast to the more favorable OPM of 9.66% reported in March 2021. The interest coverage ratio (ICR) is recorded at 3.08x, suggesting adequate capacity to meet interest obligations, although the overall profitability remains under pressure. Return on equity (ROE) is relatively low at 3.08%, while the return on capital employed (ROCE) is reported at 7.16%, indicating that the company is generating modest returns on its investments. The cash conversion cycle (CCC) of 51.93 days reflects a reasonable efficiency in managing working capital, though it has fluctuated significantly over the years. These metrics reveal that while Fabino Enterprises is navigating through profitability challenges, its operational efficiency remains a critical area of focus.
Balance Sheet Strength and Financial Ratios
The balance sheet of Fabino Enterprises reveals total assets of ₹13.01 Cr as of March 2025, up from ₹5.02 Cr in March 2023, signaling a strengthening asset base. The company has reported total borrowings of ₹1.64 Cr, which reflects a manageable debt level, resulting in a debt-to-equity ratio of 0.42x. This ratio is indicative of a relatively conservative leverage position compared to industry norms. Reserves have increased to ₹1.94 Cr, providing a buffer for future investments or operational challenges. The current ratio stands at 1.46x, suggesting that the company possesses adequate short-term liquidity to cover its liabilities. Additionally, the price-to-book value (P/BV) ratio is recorded at 1.22x, which is within the typical range for the pharmaceutical sector. Overall, Fabino Enterprises demonstrates a stable financial position with a focus on maintaining liquidity and managing its leverage.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Fabino Enterprises shows a consistent promoter holding of 56.82%, indicating a strong alignment of interests between management and shareholders. Public ownership stands at 43.18%, reflecting a balanced distribution of equity among stakeholders, although the number of shareholders has declined from 195 in March 2022 to 129 in September 2025. This reduction may raise concerns regarding investor confidence and could suggest a lack of interest or market appeal. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could further imply limited institutional backing, which typically enhances market credibility. Such a structure may affect the company’s ability to attract new investments or drive stock performance. Maintaining a robust engagement with existing shareholders and addressing the concerns of potential investors will be crucial for enhancing market perception.
Outlook, Risks, and Final Insight
Fabino Enterprises faces a mixed outlook, characterized by potential growth in revenues alongside ongoing profitability challenges. The anticipated sales surge to ₹18.00 Cr for FY 2025 is promising; however, the company must navigate risks such as fluctuating quarterly performance and a lack of institutional investor interest. The high operating profit margin of -38.24% raises concerns about cost management and operational efficiency. Additionally, while the current liquidity position appears stable, any deterioration in sales trends could strain financial health. The company must focus on improving its profitability metrics and enhancing shareholder engagement to build investor confidence. In a positive scenario, successful execution of growth strategies could lead to improved financial stability and investor interest, while adverse market conditions or operational setbacks could hinder performance and lead to further declines in market perception.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 214/84.3 | 27.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,631 Cr. | 424 | 479/192 | 95.9 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.1 Cr. | 39.7 | 40.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,857.92 Cr | 1,159.04 | 54.40 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.38 | 2.05 | 2.15 | 1.04 | 2.32 | 0.94 | 5.14 | 4.25 | 13.78 | 0.68 |
| Expenses | 2.15 | 2.11 | 2.00 | 1.03 | 2.30 | 0.87 | 5.10 | 4.21 | 13.65 | 0.94 |
| Operating Profit | 0.23 | -0.06 | 0.15 | 0.01 | 0.02 | 0.07 | 0.04 | 0.04 | 0.13 | -0.26 |
| OPM % | 9.66% | -2.93% | 6.98% | 0.96% | 0.86% | 7.45% | 0.78% | 0.94% | 0.94% | -38.24% |
| Other Income | 0.00 | 0.01 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.11 | 0.18 | 0.15 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.06 | 0.07 | 0.08 |
| Depreciation | 0.02 | 0.00 | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.04 | 0.05 |
| Profit before tax | 0.21 | -0.05 | 0.12 | 0.01 | 0.00 | 0.06 | 0.01 | 0.07 | 0.20 | -0.24 |
| Tax % | 0.00% | 0.00% | 16.67% | 0.00% | 33.33% | 0.00% | 28.57% | 55.00% | 0.00% | |
| Net Profit | 0.21 | -0.05 | 0.10 | 0.01 | 0.00 | 0.05 | 0.00 | 0.05 | 0.09 | -0.25 |
| EPS in Rs | 1.75 | -0.42 | 0.48 | 0.05 | 0.00 | 0.24 | 0.00 | 0.24 | 0.43 | -1.19 |
Last Updated: December 27, 2025, 12:37 am
Below is a detailed analysis of the quarterly data for Fabino Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.68 Cr.. The value appears to be declining and may need further review. It has decreased from 13.78 Cr. (Mar 2025) to 0.68 Cr., marking a decrease of 13.10 Cr..
- For Expenses, as of Sep 2025, the value is 0.94 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 13.65 Cr. (Mar 2025) to 0.94 Cr., marking a decrease of 12.71 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.26 Cr.. The value appears to be declining and may need further review. It has decreased from 0.13 Cr. (Mar 2025) to -0.26 Cr., marking a decrease of 0.39 Cr..
- For OPM %, as of Sep 2025, the value is -38.24%. The value appears to be declining and may need further review. It has decreased from 0.94% (Mar 2025) to -38.24%, marking a decrease of 39.18%.
- For Other Income, as of Sep 2025, the value is 0.15 Cr.. The value appears to be declining and may need further review. It has decreased from 0.18 Cr. (Mar 2025) to 0.15 Cr., marking a decrease of 0.03 Cr..
- For Interest, as of Sep 2025, the value is 0.08 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.07 Cr. (Mar 2025) to 0.08 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Sep 2025, the value is 0.05 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.04 Cr. (Mar 2025) to 0.05 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.24 Cr.. The value appears to be declining and may need further review. It has decreased from 0.20 Cr. (Mar 2025) to -0.24 Cr., marking a decrease of 0.44 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 55.00% (Mar 2025) to 0.00%, marking a decrease of 55.00%.
- For Net Profit, as of Sep 2025, the value is -0.25 Cr.. The value appears to be declining and may need further review. It has decreased from 0.09 Cr. (Mar 2025) to -0.25 Cr., marking a decrease of 0.34 Cr..
- For EPS in Rs, as of Sep 2025, the value is -1.19. The value appears to be declining and may need further review. It has decreased from 0.43 (Mar 2025) to -1.19, marking a decrease of 1.62.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:45 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 2.76 | 7.52 | 3.06 | 4.19 | 3.36 | 6.01 | 18.00 | 14.46 |
| Expenses | 2.44 | 7.20 | 2.99 | 4.09 | 3.33 | 5.90 | 17.83 | 14.59 |
| Operating Profit | 0.32 | 0.32 | 0.07 | 0.10 | 0.03 | 0.11 | 0.17 | -0.13 |
| OPM % | 11.59% | 4.26% | 2.29% | 2.39% | 0.89% | 1.83% | 0.94% | -0.90% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.29 | 0.33 |
| Interest | 0.29 | 0.20 | 0.01 | 0.01 | 0.01 | 0.02 | 0.13 | 0.15 |
| Depreciation | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.07 | 0.09 |
| Profit before tax | 0.00 | 0.10 | 0.04 | 0.07 | 0.01 | 0.06 | 0.26 | -0.04 |
| Tax % | 30.00% | 25.00% | 28.57% | 0.00% | 16.67% | 50.00% | ||
| Net Profit | 0.00 | 0.07 | 0.03 | 0.05 | 0.01 | 0.05 | 0.13 | -0.16 |
| EPS in Rs | 0.00 | 4.67 | 0.25 | 0.24 | 0.05 | 0.24 | 0.62 | -0.76 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -57.14% | 66.67% | -80.00% | 400.00% | 160.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 123.81% | -146.67% | 480.00% | -240.00% |
Fabino Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 63% |
| TTM: | 200% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 38% |
| TTM: | 160% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: December 4, 2025, 2:51 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.15 | 0.15 | 1.20 | 2.10 | 2.10 | 2.10 | 2.10 | 2.10 |
| Reserves | 0.45 | 0.52 | 0.10 | 2.00 | 2.01 | 2.06 | 2.19 | 1.94 |
| Borrowings | 2.52 | 1.08 | 0.31 | 0.05 | 0.41 | 0.84 | 1.61 | 1.64 |
| Other Liabilities | 5.43 | 1.83 | 0.65 | 0.48 | 0.50 | 4.50 | 7.11 | 4.00 |
| Total Liabilities | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 | 13.01 | 9.68 |
| Fixed Assets | 0.10 | 0.08 | 0.16 | 0.17 | 0.15 | 0.24 | 0.46 | 0.42 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 0.05 |
| Other Assets | 8.45 | 3.50 | 2.10 | 4.46 | 4.87 | 9.21 | 12.50 | 9.21 |
| Total Assets | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 | 13.01 | 9.68 |
Below is a detailed analysis of the balance sheet data for Fabino Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 2.10 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.10 Cr..
- For Reserves, as of Sep 2025, the value is 1.94 Cr.. The value appears to be declining and may need further review. It has decreased from 2.19 Cr. (Mar 2025) to 1.94 Cr., marking a decrease of 0.25 Cr..
- For Borrowings, as of Sep 2025, the value is 1.64 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1.61 Cr. (Mar 2025) to 1.64 Cr., marking an increase of 0.03 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing). It has decreased from 7.11 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 3.11 Cr..
- For Total Liabilities, as of Sep 2025, the value is 9.68 Cr.. The value appears to be improving (decreasing). It has decreased from 13.01 Cr. (Mar 2025) to 9.68 Cr., marking a decrease of 3.33 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.42 Cr.. The value appears to be declining and may need further review. It has decreased from 0.46 Cr. (Mar 2025) to 0.42 Cr., marking a decrease of 0.04 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.05 Cr..
- For Other Assets, as of Sep 2025, the value is 9.21 Cr.. The value appears to be declining and may need further review. It has decreased from 12.50 Cr. (Mar 2025) to 9.21 Cr., marking a decrease of 3.29 Cr..
- For Total Assets, as of Sep 2025, the value is 9.68 Cr.. The value appears to be declining and may need further review. It has decreased from 13.01 Cr. (Mar 2025) to 9.68 Cr., marking a decrease of 3.33 Cr..
Notably, the Reserves (1.94 Cr.) exceed the Borrowings (1.64 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.20 | -0.76 | -0.24 | 0.05 | -0.38 | -0.73 | -1.44 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 338.55 | 113.09 | 158.64 | 125.44 | 274.84 | 377.75 | 177.43 |
| Inventory Days | 988.71 | 15.36 | 62.61 | 174.83 | 147.24 | 88.59 | 26.56 |
| Days Payable | 1,024.81 | 77.34 | 63.94 | 34.76 | 45.78 | 294.40 | 152.06 |
| Cash Conversion Cycle | 302.45 | 51.11 | 157.31 | 265.51 | 376.29 | 171.94 | 51.93 |
| Working Capital Days | 19.84 | 51.93 | 165.80 | 292.70 | 444.30 | 282.40 | 103.21 |
| ROCE % | 12.32% | 2.98% | 2.78% | 0.46% | 1.68% | 7.16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.29 | 0.17 | 0.05 |
| Diluted EPS (Rs.) | 0.29 | 0.17 | 0.05 |
| Cash EPS (Rs.) | 0.67 | 0.37 | 0.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 20.02 | 19.73 | 19.59 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 20.02 | 19.73 | 19.59 |
| Revenue From Operations / Share (Rs.) | 85.89 | 100.39 | 16.00 |
| PBDIT / Share (Rs.) | 1.90 | 0.62 | 0.22 |
| PBIT / Share (Rs.) | 1.51 | 0.41 | 0.07 |
| PBT / Share (Rs.) | 0.89 | 0.23 | 0.05 |
| Net Profit / Share (Rs.) | 0.29 | 0.17 | 0.05 |
| NP After MI And SOA / Share (Rs.) | 0.29 | 0.17 | 0.05 |
| PBDIT Margin (%) | 2.21 | 0.62 | 1.42 |
| PBIT Margin (%) | 1.76 | 0.41 | 0.47 |
| PBT Margin (%) | 1.04 | 0.23 | 0.36 |
| Net Profit Margin (%) | 0.33 | 0.16 | 0.32 |
| NP After MI And SOA Margin (%) | 0.33 | 0.16 | 0.32 |
| Return on Networth / Equity (%) | 1.45 | 0.86 | 0.26 |
| Return on Capital Employeed (%) | 5.29 | 1.59 | 0.35 |
| Return On Assets (%) | 0.34 | 0.23 | 0.21 |
| Long Term Debt / Equity (X) | 0.42 | 0.30 | 0.09 |
| Total Debt / Equity (X) | 0.42 | 0.30 | 0.09 |
| Asset Turnover Ratio (%) | 1.09 | 2.07 | 0.00 |
| Current Ratio (X) | 1.46 | 1.51 | 10.73 |
| Quick Ratio (X) | 1.36 | 1.37 | 8.07 |
| Inventory Turnover Ratio (X) | 14.21 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 3.08 | 3.48 | 12.01 |
| Interest Coverage Ratio (Post Tax) (X) | 1.47 | 1.95 | 3.72 |
| Enterprise Value (Cr.) | 6.69 | 9.52 | 6.46 |
| EV / Net Operating Revenue (X) | 0.37 | 0.45 | 1.92 |
| EV / EBITDA (X) | 16.78 | 72.62 | 135.37 |
| MarketCap / Net Operating Revenue (X) | 0.28 | 0.39 | 1.87 |
| Price / BV (X) | 1.22 | 2.01 | 1.53 |
| Price / Net Operating Revenue (X) | 0.28 | 0.39 | 1.88 |
| EarningsYield | 0.01 | 0.00 | 0.00 |
After reviewing the key financial ratios for Fabino Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 5. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 5. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 3. It has increased from 0.37 (Mar 24) to 0.67, marking an increase of 0.30.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.02. It has increased from 19.73 (Mar 24) to 20.02, marking an increase of 0.29.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.02. It has increased from 19.73 (Mar 24) to 20.02, marking an increase of 0.29.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 85.89. It has decreased from 100.39 (Mar 24) to 85.89, marking a decrease of 14.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.90. This value is below the healthy minimum of 2. It has increased from 0.62 (Mar 24) to 1.90, marking an increase of 1.28.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.51. This value is within the healthy range. It has increased from 0.41 (Mar 24) to 1.51, marking an increase of 1.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.89. This value is within the healthy range. It has increased from 0.23 (Mar 24) to 0.89, marking an increase of 0.66.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 2. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 2. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For PBDIT Margin (%), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 10. It has increased from 0.62 (Mar 24) to 2.21, marking an increase of 1.59.
- For PBIT Margin (%), as of Mar 25, the value is 1.76. This value is below the healthy minimum of 10. It has increased from 0.41 (Mar 24) to 1.76, marking an increase of 1.35.
- For PBT Margin (%), as of Mar 25, the value is 1.04. This value is below the healthy minimum of 10. It has increased from 0.23 (Mar 24) to 1.04, marking an increase of 0.81.
- For Net Profit Margin (%), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 5. It has increased from 0.16 (Mar 24) to 0.33, marking an increase of 0.17.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 8. It has increased from 0.16 (Mar 24) to 0.33, marking an increase of 0.17.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 15. It has increased from 0.86 (Mar 24) to 1.45, marking an increase of 0.59.
- For Return on Capital Employeed (%), as of Mar 25, the value is 5.29. This value is below the healthy minimum of 10. It has increased from 1.59 (Mar 24) to 5.29, marking an increase of 3.70.
- For Return On Assets (%), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has increased from 0.23 (Mar 24) to 0.34, marking an increase of 0.11.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 0.42, marking an increase of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 0.42, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.09. It has decreased from 2.07 (Mar 24) to 1.09, marking a decrease of 0.98.
- For Current Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 1.5. It has decreased from 1.51 (Mar 24) to 1.46, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.36. This value is within the healthy range. It has decreased from 1.37 (Mar 24) to 1.36, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.21. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 14.21, marking an increase of 14.21.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.08. This value is within the healthy range. It has decreased from 3.48 (Mar 24) to 3.08, marking a decrease of 0.40.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 3. It has decreased from 1.95 (Mar 24) to 1.47, marking a decrease of 0.48.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.69. It has decreased from 9.52 (Mar 24) to 6.69, marking a decrease of 2.83.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.45 (Mar 24) to 0.37, marking a decrease of 0.08.
- For EV / EBITDA (X), as of Mar 25, the value is 16.78. This value exceeds the healthy maximum of 15. It has decreased from 72.62 (Mar 24) to 16.78, marking a decrease of 55.84.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.28, marking a decrease of 0.11.
- For Price / BV (X), as of Mar 25, the value is 1.22. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.22, marking a decrease of 0.79.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.28, marking a decrease of 0.11.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fabino Enterprises Ltd:
- Net Profit Margin: 0.33%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 5.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.45% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.47
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.36
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 54.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.42
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.33%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Jeevan Vihar Extension Near, Shubham Garden, Sonipat Haryana 131001 | info@fabinolife.com www.fabinolife.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Aditya Jain | Managing Director |
| Mr. Arihant Jain | Non Executive Director |
| Mr. Sumit Malik | Non Executive Director |
| Mr. Kuldeep Singh Solanki | Independent Director |
| Mrs. Tesu Alakh | Independent Director |
| Mrs. Vandana Jain | Additional Director |
FAQ
What is the intrinsic value of Fabino Enterprises Ltd?
Fabino Enterprises Ltd's intrinsic value (as of 07 January 2026) is ₹7.24 which is 47.54% lower the current market price of ₹13.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹2.91 Cr. market cap, FY2025-2026 high/low of ₹39.0/13.0, reserves of ₹1.94 Cr, and liabilities of ₹9.68 Cr.
What is the Market Cap of Fabino Enterprises Ltd?
The Market Cap of Fabino Enterprises Ltd is 2.91 Cr..
What is the current Stock Price of Fabino Enterprises Ltd as on 07 January 2026?
The current stock price of Fabino Enterprises Ltd as on 07 January 2026 is ₹13.8.
What is the High / Low of Fabino Enterprises Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fabino Enterprises Ltd stocks is ₹39.0/13.0.
What is the Stock P/E of Fabino Enterprises Ltd?
The Stock P/E of Fabino Enterprises Ltd is .
What is the Book Value of Fabino Enterprises Ltd?
The Book Value of Fabino Enterprises Ltd is 19.2.
What is the Dividend Yield of Fabino Enterprises Ltd?
The Dividend Yield of Fabino Enterprises Ltd is 0.00 %.
What is the ROCE of Fabino Enterprises Ltd?
The ROCE of Fabino Enterprises Ltd is 7.16 %.
What is the ROE of Fabino Enterprises Ltd?
The ROE of Fabino Enterprises Ltd is 3.08 %.
What is the Face Value of Fabino Enterprises Ltd?
The Face Value of Fabino Enterprises Ltd is 10.0.